Should I Buy PCSA? PCSA 2026 Analysis

Should You Buy Processa Pharmaceuticals Inc (PCSA) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

3.140

1 Day change

52 Week Range

20.230

Analysis Updated At

2026/01/26

Processa Pharmaceuticals Inc (PCSA) is not a strong buy for a beginner, long-term investor at this time. The stock lacks positive momentum, has weak financial performance, and no significant catalysts or trading signals to justify immediate investment. Holding off for now is recommended.

Technical Analysis

The MACD is slightly positive but contracting, indicating weakening momentum. RSI is neutral at 45.485, showing no clear overbought or oversold condition. Moving averages are bearish (SMA_200 > SMA_20 > SMA_5), and the stock is trading below the pivot level of 3.374, suggesting a bearish trend.

Options Data

Positive Catalysts

NULL identified. No recent news or significant insider/hedge fund activity. No congress trading data available.

Neutral/Negative Catalysts

The stock has a 40% chance of declining in the next week (-0.33%) and month (-6.82%). Financial performance is weak, with negative net income and EPS dropping significantly (-92.99% YoY).

Financial Performance

In Q3 2025, revenue remained at $0 with no growth. Net income was -$3,436,573, a slight improvement of 1.53% YoY. EPS dropped drastically by -92.99% YoY to -1.81, indicating worsening profitability. Gross margin remains at 0%.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target data available.

Analyst Rating

Wall Street analysts forecast PCSA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PCSA is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Buy

Hold

Sell

Current: 3.140

Low

Averages

High

Current: 3.140

Low

Averages

High

H.C. Wainwright

Raghuram Selvaraju

Buy

downgrade

$2 -> $1

AI Analysis

2025-09-02

Reason

H.C. Wainwright

Raghuram Selvaraju

Price Target

$2 -> $1

AI Analysis

2025-09-02

downgrade

Buy

Reason

H.C. Wainwright analyst Raghuram Selvaraju lowered the firm's price target on Processa Pharmaceuticals to $1 from $2 and keeps a Buy rating on the shares. The firm cites equity dilution from the strategic investment for the target cut.

H.C. Wainwright

Buy

downgrade

$6 -> $2

2025-06-30

Reason

H.C. Wainwright

Price Target

$6 -> $2

2025-06-30

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on Processa Pharmaceuticals to $2 from $6 and keeps a Buy rating on the shares after the company recently announced that it had raised a total of $7M in gross proceeds from an equity financing involving the sale of common shares, pre-funded warrants and warrants to purchase common stock. The equity financing lengthens the runway through key clinical development milestone, but the firm is lowering its price target to account for dilution, the analyst noted.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for PCSA

Unlock Now

PCSA Should I Buy

PCSA Should I Buy

Should You Buy Processa Pharmaceuticals Inc (PCSA) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch